# sumanta-barman.github.io



# Dr. Sumanta Barman




<img src="SB.jpg" alt="Profile Picture" width="200">


---

## About Me

I am a research scientist specializing in Central Nervous System (CNS) autoimmune diseases with expertise in immunology, molecular biology, immunogenomics, transcriptomics, proteomics and bioinformatics. My work focuses on analyzing human immune repertoires using next-generation sequencing (NGS) and exploring the potential of AI in precision medicine. As a highly skilled research scientist with a focus on Central nervous system (CNS) autoimmune diseases, I possess extensive expertise in various aspects of human immune repertoire (IR) analysis, "-omics" technologies, especially immunogenomics/transcriptomics, single B cell recombinant antibody technology, and bioinformatics. My expertise in next-generation sequencing (NGS), both in laboratory and computational, as well as my proficiency in bulk and single cell RNA-Seq data analysis (IR & Transcriptomics), quantitative PCR, flow cytometry, affinity chromatography, cell culture, and more, allow me to extract valuable insights and drive progress in the field of neuroimmunology. My mastery of data analysis using Python and R, alongside machine learning and deep learning-based tools, empowers me to make informed decisions based on data and evidence. In addition, I possess good knowledge of statistical approaches, utilizing tools such as R, SPSS and GraphPad Prism, to derive meaningful insights and statistical interpretations in research. Furthermore, I am deeply enthusiastic about the application of artificial intelligence (AI) in healthcare and its potential to revolutionize precision medicine.

My dedication and perseverance have resulted in numerous scientific publications and presentations, both oral and poster, at international conferences. Additionally, I have had the opportunity to mentor multi-cultural students in all aspects of research, including project conception, methodology, data analysis, presentation, and report writing for bachelor's, master's, and PhD theses.

I have extensive expertise in evaluating the treatment effect of various disease-modifying therapies, including Alemtuzumab (Lemtrada) from Sanofi-Genzyme, Fingolimod (Gilenya) from Novartis, and Ocrelizumab (Ocrevus) from Roche, on the peripheral immune repertoire of multiple sclerosis patients. I also have experience in the development of recombinant human monoclonal antibodies from clonally expanded plasma cells (cePc) of patients with autoimmune and viral encephalitis. In addition, I have a comprehensive understanding of multi-omics technologies, as well as proficiency in R, Python, deep learning, and machine learning-based biological data analysis.

---

## Expertise

- **Immunogenomics/Transcriptomics**
- **NGS Data Analysis**
- **Single B Cell Recombinant Antibodies**
- **Bioinformatics**
- **Bulk and Single Cell RNA-Seq Analysis**
- **Quantitative PCR**
- **Flow Cytometry**
- **Affinity Chromatography**
- **Cell Culture**
- **Statistical Analysis using R, SPSS, GraphPad Prism**
- **Machine Learning and Deep Learning**
- **Multi-omics Technologies**

---

## Research Highlights

- Investigating treatment effects of disease-modifying therapies in multiple sclerosis patients
- Development of recombinant human monoclonal antibodies for autoimmune and viral encephalitis
- Mentoring students in research methodology and data analysis
- Contributed to scientific publications and presentations at international conferences

---

## Tools & Technologies

- **Programming:** Python, R
- **Data Analysis:** Pandas, NumPy, SciPy
- **Machine Learning:** Scikit-learn, TensorFlow, PyTorch
- **Bioinformatics:** BWA, SAMtools, Bioconductor
- **Statistical Analysis:** RStudio, SPSS, GraphPad Prism

---

## Research articals

# Research

## Selected Publications

1. **[Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity](https://academic.oup.com/brain/article/145/5/1711/6590581)**  
   *Authors:* Tobias Ruck#, <strong>Sumanta Barman#</strong>, Andreas Schulte-Mecklenbeck#, Steffen Pfeuffer#, Falk Steffen, Christopher Nelke, Christina B Schroeter, Alice Willison, Michael Heming, Thomas Müntefering, Nico Melzer, Julia Krämer, Maren Lindner, Marianne Riepenhausen, Catharina C Gross, Luisa Klotz, Stefan Bittner, Paolo A Muraro, Tilman Schneider-Hohendorf, Nicholas Schwab, Gerd Meyer zu Hörste, Norbert Goebels, Sven G Meuth, Heinz Wiendl. *<strong>#equally contributing first authors</strong>*
   
   *Journal:* Brain  
   *Year:* 2022

    <a href="https://academic.oup.com/brain/article/145/5/1711/6590581"><img src="awac064f4.jpeg" alt="Thumbnail" width="200"></a>
    

2. **[NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody](https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.444)**  
   *Authors:* Manish Malviya#, <strong>Sumanta Barman#</strong>, Kristin S Golombeck#, Jesús Planagumà#, Francesco Mannara#, Nathalie Strutz‐Seebohm, Claudia Wrzos, Fatih Demir, Christine Baksmeier, Julia Steckel, Kim Kristin Falk, Catharina C Gross, Stjepana Kovac, Kathrin Bönte, Andreas Johnen, Klaus‐Peter Wandinger, Elena Martín‐García, Albert J Becker, Christian E Elger, Nikolaj Klöcker, Heinz Wiendl, Sven G Meuth, Hans‐Peter Hartung, Guiscard Seebohm, Frank Leypoldt, Rafael Maldonado, Christine Stadelmann, Josep Dalmau, Nico Melzer, Norbert Goebels. *<strong>#equally contributing first authors</strong>*
   
   *Journal:* Annals of clinical and translational neurology  
   *Year:* 2017
   
   <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.444"><img src="https://onlinelibrary.wiley.com/cms/asset/20fe6556-ba39-4887-9dbb-0d067072d452/acn3444-fig-0004-m.jpg" alt="Thumbnail" width="200"></a>

   
3. **[Myelinating Co-Culture as a Model to Study Anti-NMDAR Neurotoxicity](https://www.mdpi.com/1422-0067/24/1/248)**  
   *Authors:* Mercedeh Farhat Sabet, <strong>Sumanta Barman</strong>, Mathias Beller, Sven G Meuth, Nico Melzer, Orhan Aktas, Norbert Goebels, Tim Prozorovski.
   
   *Journal:* International Journal of Molecular Sciences  
   *Year:* 2023
   
   <a href="https://www.mdpi.com/1422-0067/24/1/248"><img src="https://www.mdpi.com/ijms/ijms-24-00248/article_deploy/html/images/ijms-24-00248-g001.png" alt="Thumbnail" width="200"></a>

4. **[Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1198860/full)**  
   *Authors:* Saskia Räuber, Christopher Nelke, Christina B Schroeter,  <strong>Sumanta Barman</strong>, Marc Pawlitzki, Jens Ingwersen, Katja Akgün, Rene Günther, Alejandra P Garza, Michaela Marggraf, Ildiko Rita Dunay, Stefanie Schreiber, Stefan Vielhaber, Tjalf Ziemssen, Nico Melzer, Tobias Ruck, Sven G Meuth, Michael Herty.
   
   *Journal:* Frontiers in Immunology  
   *Year:* 2023
   
   <a href="https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1198860/full"><img src="https://www.frontiersin.org/files/Articles/1198860/fimmu-14-1198860-HTML/image_m/fimmu-14-1198860-g004.jpg" alt="Thumbnail" width="300"></a>
   
5. **[N‐methyl‐D‐aspartate receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function](https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25699)**  
   *Authors:* Carlos Matute, Ana Palma, María Paz Serrano‐Regal, Estibaliz Maudes, <strong>Sumanta Barman#</strong>, María Victoria Sánchez‐Gómez, María Domercq, Norbert Goebels, Josep Dalmau. 
   
   *Journal:* Annals of neurology  
   *Year:* 2020
   
   <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25699"><img src="ana25699-fig-0001-m.png" alt="Thumbnail" width="300"></a>


3. **N‐methyl‐D‐aspartate receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function**  
   *Authors:* Carlos Matute, Ana Palma, María Paz Serrano‐Regal, Estibaliz Maudes, <strong>Sumanta Barman#</strong>, María Victoria Sánchez‐Gómez, María Domercq, Norbert Goebels, Josep Dalmau 
   *Journal:* Annals of neurology  
   *Year:* 2020  
   *Citations:* 32

5. **Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity**  
   *Authors:* T Ruck, S Barman, A Schulte-Mecklenbeck, S Pfeuffer, F Steffen, C Nelke, ...  
   *Journal:* Brain  
   *Year:* 2022  
   *Citations:* 29

6. **Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis**  
   *Authors:* SK Wright, RE Rosch, MA Wilson, MA Upadhya, DR Dhangar, ...  
   *Journal:* Communications biology  
   *Year:* 2021  
   *Citations:* 22

7. **Dose‐dependent inhibition of demyelination and microglia activation by IVIG**  
   *Authors:* M Winter, C Baksmeier, J Steckel, S Barman, M Malviya, M Harrer‐Kuster, ...  
   *Journal:* Annals of clinical and translational neurology  
   *Year:* 2016  
   *Citations:* 21

8. **[Myelinating Co-Culture as a Model to Study Anti-NMDAR Neurotoxicity](https://www.mdpi.com/1422-0067/24/1/248)**  
   *Authors:* Mercedeh Farhat Sabet, Sumanta Barman, Mathias Beller, Sven G Meuth, Nico Melzer, Orhan Aktas, Norbert Goebels, Tim Prozorovski.
    
   *Journal:* International Journal of Molecular Sciences
   *Year:* 2023

      <a href="https://www.mdpi.com/1422-0067/24/1/248"><img src="https://www.mdpi.com/ijms/ijms-24-00248/article_deploy/html/images/ijms-24-00248-g001.png" alt="Thumbnail" width="200"></a>
   

...

## Complete List of Publications

- You can also find a complete list of my publications [here](https://scholar.google.com/citations?user=GUAu_j0AAAAJ&hl=en).

---

## Contact Me

- [Email](mailto:barman.sumanta@gmail.com)
- [LinkedIn](https://www.linkedin.com/in/dr-sumanta-barman-327954143/)
- [GitHub](https://github.com/sumanta-barman)
- [Google Scholar](https://scholar.google.com/citations?user=GUAu_j0AAAAJ&hl=en)

---

Feel free to reach out if you are interested in collaboration or have any inquiries related to my research!



